Supplementary Figure S2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study

Míreanna comhchosúla

• Figure 1 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
  de réir: Ruiliang Wang (17333340)
  Foilsithe / Cruthaithe: (2025)
• Figure 2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
  de réir: Ruiliang Wang (17333340)
  Foilsithe / Cruthaithe: (2025)
• Figure 3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
  de réir: Ruiliang Wang (17333340)
  Foilsithe / Cruthaithe: (2025)
• Figure 4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
  de réir: Ruiliang Wang (17333340)
  Foilsithe / Cruthaithe: (2025)
• Figure 5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
  de réir: Ruiliang Wang (17333340)
  Foilsithe / Cruthaithe: (2025)